Pioneering generative biology to create breakthrough therapeutics.

Fidelity Management and Research Company

Morningside Venture Investments

Morningside Ventures

Flagship Pioneering

T. Rowe Price

Abu Dhabi Investment Authority

Alaska Permanent Fund

Altitude Life Science Ventures

ARCH Venture Partners

Generate:Biomedicines

ICYMI: At the 2023 The Galien Foundation Forum our CEO Michael Nally joined a panel of industry leaders titled “Conceiving, Creating and Building BioPharma Companies.”  
 
Mike and fellow panelists discussed the future of the biopharma industry – including the #AI revolution occurring at the intersection of biology and technology. As Mike shared: "I don't think a company can be born without a computational foundation going forward. I think it's going to be increasingly difficult to start companies without it." 
 
Learn more: https://lnkd.in/ewi6jSHY  

#UnapologeticallyScientific | #GenerativeBiology | #ProteinEngineering

In this article by Ryan Cross in Endpoints News, Alexandra Snyder, MD and Marco Davila discuss our new collaboration with Roswell Park Comprehensive Cancer Center. As Ryan states, we aim to “crack one of the toughest problems in cell therapy: getting CAR-T cells to target solid tumors.”   
 
In our collaboration, we will engineer and develop CAR-T drugs to treat solid tumors. These therapies are so-called "armored CARs" that include both a functionally optimized CAR protein and an additional factor targeting the harsh tumor microenvironment. 
 
Read more:  

#ProteinEngineering | #PatientFocusedDrugDevelopment

Today we announced a strategic collaboration with Roswell Park Comprehensive Cancer Center Park to discover and develop chimeric antigen receptor (CAR) T-cell therapies and armoring technologies for up to three oncology targets, including in ovarian cancer and other solid tumors. 
 
By combining the programmability and scalability of The Generate Platform with Roswell Park Comprehensive Cancer Center’s expertise in cell therapy design, clinical development, and manufacturing, we hope to bring best-in-class cell therapies to patients who are desperately in need of new treatment options. 
 
#GenerativeAI | #PatientFocusedDrugDevelopment 
 
Learn more:  https://lnkd.in/eRCy_mkB

On behalf of all of us at #TeamGenerate: Congratulations to fellow #FlagshipFounded company Tessera Therapeutics for receiving the Prix Galien 2023 Best Startup Award, which recognizes innovative emerging pharmaceutical enterprises making a profound impact on human health.

Today, Noubar Afeyan, Ph.D., our Co-founder and Chairman of the Board and Founder and Chief Executive Officer of Flagship Pioneering, presented the inaugural Chairman’s Award to John Ingraham, our Head of Machine Learning.  
 
The Chairman’s Award recognizes Generators for their commitment to answering daring "what if" questions by dreaming big, leaping boldly, and imagining alternative futures without constraint of reason.   
 
As a pioneer of #GenerativeBiology, John has applied his innovative thinking in #MachineLearning and #GenerativeAI to build tools that are making a profound impact on the field of #ProteinEngineering.  
 
Congratulations John for this exciting recognition!  
 
#FlagshipFounded | #UnapologeticallyScientific

On October 26, our CEO Michael Nally will speak as part of a The Galien Foundation Forum panel, “Conceiving, Creating and Building BioPharma Companies.” 
 
Chaired by John Maraganore, Founding CEO of Alnylam Pharmaceuticals, Mike and fellow panelists Sangeeta Bhatia, Professor of Electrical Engineering and Computer Science at MIT, Adam Koppel, Partner, Bain Capital Life Sciences, and Daphne Zohar, Founder & CEO of PureTech Health, will discuss the challenges and opportunities facing innovative new enterprises in the biotech industry.  
 
#GalienForum 
 
Learn more: https://bit.ly/3Fjkyxx

Jason Silvers, our Chief Financial Officer, will explore the evolving landscape of deal-making in a panel discussion at the Fierce Biotech Summit on October 17.  
 
Jason will offer his unique perspective on how biotech leaders can leverage strategic collaborations to drive innovation in an era of increasing market complexities.  

Learn more: https://bit.ly/48RMt5e

As a recipient of the 2023 Transform 10 Award, hear our Chief People Officer Beth Anton Grous talk about the future of work and how she’s capitalizing on these shifting sentiments to position our robust people-first culture for future growth.
 
#FiercelyUnited I #TeamGenerate

A recent Genetic Engineering & Biotechnology News article by MaryAnn L. highlights our work designing novel biologic drugs, including adeno-associated virus (AAV) therapies. 
 
Featuring Dr. Alexandra Snyder, MD, EVP of R&D, and Stephen Goldfless, PhD, Head of G:Labs Technology and Strategy, the article explains how we use The Generate Platform to overcome the challenges of pre-existing and adaptive immunity to therapeutics. 

#GenerativeAI | #ProteinEngineering

https://lnkd.in/eepSDw_G

On October 12, Adam Root, our VP of Protein Sciences, will explain how we are turning drug discovery into a technological pursuit in a webinar hosted by Drug Discovery World and Thermo Fisher Scientific. Learn more 👇 
 https://lnkd.in/eud_AxJS

Viewport Meta

IPhone / Mobile Compatible

Euro

Google Tag Manager

Apple Mobile Web Clips Icon

Google Analytics

Content Delivery Network

Global Site Tag

Organization Schema

Google Analytics 4

Co-Founder & Chief Technology Officer

Gevorg Grigoryan

Chief Scientific Officer

Mike Nohaile

Vice President of Preclinical Discovery and Development

Kristen Hopson

Senior Director, Total Rewards and People Operations

Alissa Cartun

Associate Director, Informatics Data Systems

Alok Saldanha

Associate Director, Infectious Disease

Amarendra Pegu

Director, R&D Strategy

Ana Dordea

Senior Director Regulatory Affairs

Andrew Robertson

Associate Director, People Strategy and Operations

Ben Marshall

Senior Director of Quantitative Biology

Brett Hannigan

Noubar Afeyan

Michael Nohaile

Sophie de Boer

Co-Founder

Dimitris Agrafiotis

Chief Digital Officer

Lisa Wyman

Senior Vice President Technical Operations

Chairman and Co-Founder

Daria Hazuda

Head of Infectious Disease and Vaccines Research

Molly Gibson

Co-Founder and Chief Innovation Officer

Sean Martin

Chief Legal Officer and General Counsel

Greater Boston Area Startups with Female Founders

Northeastern US Late Stage Companies With More Than 10 Employees

Greater Boston Area Biotechnology Companies

Biotechnology Unicorn Startups

Generate Biomedicines is a biotechnological company focusing on creating breakthrough medicines. It pioneers in the field of Generative Biology, a revolutionary approach to drug development that allows them to program protein-based modalities for the first time.

Alumni Ventures

Series C - Generate Biomedicines

Series B - Generate Biomedicines

Series A - Generate Biomedicines

Somerville

Massachusetts

United States

North America

Generate Biomedicines

Generate:Biomedicines Expands Board of Directors with the Appointment of Rupert Vessey, M.D., Ph.D., and Nancy Simonian, M.D.

Generate:Biomedicines Expands Board of Directors with the Appointment of Rupert Vessey, M.D., Ph.D., and Nancy ...

25. Generate: Biomedicines

Generate:Biomedicines Expands C-suite with Chief Corporate Affairs Officer and Chief Technical Operations Officer

The Escalator: Bristol Myers Squibb, Generate:Biomedicines, Sandoz and more

Generate:Biomedicines Hires Kym White To Lead Corporate Affairs

Protein Engineering Market Size Estimated to Reach USD 15.25 Bn by 2032

A machine learning-powered platform used to create new drugs on demand across various biologic modalities, increasing the speed of therapeutic identification and validation.

An AI model that programs novel proteins with targeted properties, made available as open-source to accelerate progress in generative biology.

Includes a range of investigational therapies such as GB-0895 for asthma and GB-0669 targeting SARS-CoV-2, with plans to deliver additional assets to the clinic.

An agreement with Amgen to develop novel proteins, with Amgen exercising rights to opt in for a sixth program under the collaboration.

Canada

United Kingdom

Europe

Philippines

Asia

India

Head of Corporate Affairs

Global Head of Strategy and Science Communications

Global Head of Strategy Communications

Head of CEO and Executive Communications

Head of R&D Strategy and Communications

Head of Worldwide Medical Communications

Global Thought Leader Strategy

Meeting and Convention Management

Senior Programs Manager

Marketing Event Planner

HR Communications

Investor Relations Specialist

Megan McLaughlin

Chief Information Security Officer

Advisory Board Member

VP & Chief Information Security Officer

Captain, Military Intelligence

Tom Doughty

Senior Director CMC Strategic Planning & Operations

CMC Operations

Alliance Management, NIBR BD&L

Head of External Manufacturing

Farrah Chaudhary

Associate Director

Senior Scientist

Associate Director at Generate Biomedicines

Mary Thomas

Head, Antibody Research, Virology Core

Staff Scientist, Virology Core

Research Fellow

Graduate Student Researcher

Principal Scientist

Post Doctoral

Researcher

PhD student

Lab instructor

Roy Ziblat

Chief People Officer

Member, Board Of Directors

Venture Advisor

Senior Vice President & Chief People Officer

Senior Vice President, Global Human Resources

Director, Human Resources

Manager, Employee Communications & Training

Chief People Officer at Generate Biomedicines/Board Member/Venture Advisor

Beth Grous

Associate Director of Portfolio & Program Management

Associate Director - Portfolio & Program Management

Sr. Research Scientist

Sr. Research Scientist, Disease Modeling

Research Scientist I - Human Disease Modeling

Sr. Research Associate - neurobiology and molecular pharmacology

Research Associate

Intern

Meghan Garcia

CEO at Generate Biomedicines

CEO/Partner

Board Member

Member Board Of Directors

Chief Marketing Officer, Human Health

President, Merck Vaccines

Managing Director, Sweden

Executive Director, Strategic Initiatives and Operations

Executive Director, Global Human Health Operations and Execution

Director Business Development

Director, Investor Relations

Manager, Worldwide Human Health Financial Services

Senior Financial Analyst, Corporate Financial Services

CEO at Generate Biomedicines and CEO/Partner at Flagship Pioneering

Michael Nally

Director of Software Engineering

Principal Software Engineer

Senior Analyst Programmer

Postdoctoral Associate

Graduate Research Associate

Director of Software Engineer at Generate Biomedicines, Inc.

Luis L.

Associate Director, Accounting

Senior Manager, Accounting

Accounting Manager

Senior Accountant

Accounting Analyst

Accountant

Associate Director, Accounting at Generate Biomedicines, Inc.

Heather Adamson

Associate Director Software Engineering

Technical Associate Director

Software Developer

IT/Business Analyst

Tech Team

Software Engineer

PhRMA Fellow

Postdoctoral Researcher

Postdoctoral Scholar

Graduate Student

UROP

Associate Director in Preclinical Research

Scientist

Post doctoral research fellow

Associate Director in Preclinical Research at Generate Biomedicines

Melissa Conerly

Director of Novel Tx Production & Characterization

Principal Research Associate

Director

Dana Lord

news impact assignment basic	general
public peers	general
news daily refresh	general	Aug 6, 2024 9:20 PM	28d728dd
news processing daily refresh	general	May 20, 2024 3:57 PM	3fccfdaa
news impact assignment daily	general	May 21, 2024 1:57 PM	f5f4d5f9
news processing basic	general
company summary	general
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	5261471f
crunchbase profile	general	Nov 25, 2024 11:36 AM	6dc18ee5
li profile	general	Dec 1, 2023 12:16 AM	2731bd0c
translate crunchbase fundingrounds	general	Nov 25, 2024 3:03 PM	13acb8cb
peers	general
news basic	general
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:GENERATEBIOMEDICINES

Generate Biomedicines